Literature DB >> 23907854

RNA protein interactions governing expression of the most abundant protein in human body, type I collagen.

Branko Stefanovic1.   

Abstract

Type I collagen is the most abundant protein in human body. The protein turns over slowly and its replacement synthesis is low. However, in wound healing or in pathological fibrosis the cells can increase production of type I collagen several hundred fold. This increase is predominantly due to posttranscriptional regulation, including increased half-life of collagen messenger RNAs (mRNAs) and their increased translatability. Type I collagen is composed of two α1 and one α2 polypeptides that fold into a triple helix. This stoichiometry is strictly regulated to prevent detrimental synthesis of α1 homotrimers. Collagen polypeptides are co-translationally modified and the rate of modifications is in dynamic equilibrium with the rate of folding, suggesting coordinated translation of collagen α1(I) and α2(I) polypeptides. Collagen α1(I) mRNA has in the 3' untranslated region (UTR) a C-rich sequence that binds protein αCP, this binding stabilizes the mRNA in collagen producing cells. In the 5' UTR both collagen mRNAs have a conserved stem-loop (5' SL) structure. The 5' SL is critical for high collagen expression, knock in mice with disruption of the 5' SL are resistant to liver fibrosis. the 5' SL binds protein LARP6 with strict sequence specificity and high affinity. LARP6 recruits RNA helicase A to facilitate translation initiation and associates collagen mRNAs with vimentin and nonmuscle myosin filaments. Binding to vimentin stabilizes collagen mRNAs, while nonmuscle myosin regulates coordinated translation of α1(I) and α2(I) mRNAs. When nonmuscle myosin filaments are disrupted the cells secrete only α1 homotrimers. Thus, the mechanism governing high collagen expression involves two RNA binding proteins and development of cytoskeletal filaments.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23907854      PMCID: PMC3748166          DOI: 10.1002/wrna.1177

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev RNA        ISSN: 1757-7004            Impact factor:   9.957


  82 in total

Review 1.  In situ localization of collagen production by chondrocytes and osteoblasts in fracture callus.

Authors:  M Sandberg; H Aro; P Multimäki; H Aho; E Vuorio
Journal:  J Bone Joint Surg Am       Date:  1989-01       Impact factor: 5.284

2.  Circumstances and mechanisms of inhibition of translation by secondary structure in eucaryotic mRNAs.

Authors:  M Kozak
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

3.  A highly conserved, 5' untranslated, inverted repeat sequence is ineffective in translational control of the alpha 1(I) collagen gene.

Authors:  P Bornstein; J McKay; S Devarayalu; S C Cook
Journal:  Nucleic Acids Res       Date:  1988-10-25       Impact factor: 16.971

4.  Clinical features of homozygous alpha 2(I) collagen deficient osteogenesis imperfecta.

Authors:  F M Pope; A C Nicolls; G Osse; K W Lee
Journal:  J Med Genet       Date:  1986-08       Impact factor: 6.318

5.  Collagen polymorphism: isolation and partial characterization of alpha 1(I)-trimer molecules in normal human skin.

Authors:  J Uitto
Journal:  Arch Biochem Biophys       Date:  1979-02       Impact factor: 4.013

6.  Myosin light chain kinase inhibitors ML-7 and ML-9 inhibit mouse lung carcinoma cell attachment to the fibronectin substratum.

Authors:  M Isemura; T Mita; K Satoh; K Narumi; M Motomiya
Journal:  Cell Biol Int Rep       Date:  1991-10

7.  A uniquely conserved regulatory signal is found around the translation initiation site in three different collagen genes.

Authors:  Y Yamada; M Mudryj; B de Crombrugghe
Journal:  J Biol Chem       Date:  1983-12-25       Impact factor: 5.157

8.  Synthesis of type I collagen in healing wounds in humans.

Authors:  K Haukipuro; J Melkko; L Risteli; M Kairaluoma; J Risteli
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

9.  Liver collagen synthesis in murine schistosomiasis.

Authors:  M A Dunn; M Rojkind; K S Warren; P K Hait; L Rifas; S Seifter
Journal:  J Clin Invest       Date:  1977-04       Impact factor: 14.808

10.  Desmin/vimentin intermediate filaments are dispensable for many aspects of myogenesis.

Authors:  T Schultheiss; Z X Lin; H Ishikawa; I Zamir; C J Stoeckert; H Holtzer
Journal:  J Cell Biol       Date:  1991-09       Impact factor: 10.539

View more
  16 in total

1.  What are the therapeutic implications of increased collagen expression in melanoma cells treated with vemurafenib?

Authors:  Constance E Brinckerhoff
Journal:  Melanoma Manag       Date:  2016-02-18

2.  Insulin-like growth factor 1 signaling in tenocytes is required for adult tendon growth.

Authors:  Nathaniel P Disser; Kristoffer B Sugg; Jeffrey R Talarek; Dylan C Sarver; Brennan J Rourke; Christopher L Mendias
Journal:  FASEB J       Date:  2019-09-16       Impact factor: 5.191

3.  Delayed Diagnosis of Osteogenesis Imperfecta: A Differential Diagnosis Guided by Competing Ocular Findings and a Lack of Family History.

Authors:  Eric B Nguyen; Erica Y Kim; Michelle I Malwane; Sergio Trejo; José R Cucalón-Calderón
Journal:  Cureus       Date:  2022-06-10

4.  Discovery of a Lead Compound for Specific Inhibition of Type I Collagen Production in Fibrosis.

Authors:  Branko Stefanovic; Heather A Michaels; Adel Nefzi
Journal:  ACS Med Chem Lett       Date:  2021-02-24       Impact factor: 4.345

5.  Type-1 pericytes accumulate after tissue injury and produce collagen in an organ-dependent manner.

Authors:  Alexander Birbrair; Tan Zhang; Daniel Clark Files; Sandeep Mannava; Thomas Smith; Zhong-Min Wang; Maria Laura Messi; Akiva Mintz; Osvaldo Delbono
Journal:  Stem Cell Res Ther       Date:  2014-11-06       Impact factor: 6.832

6.  The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.

Authors:  Molly H Jenkins; Walburga Croteau; David W Mullins; Constance E Brinckerhoff
Journal:  Matrix Biol       Date:  2015-05-16       Impact factor: 11.583

Review 7.  The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis.

Authors:  Jessica Lawrence; Richard Nho
Journal:  Int J Mol Sci       Date:  2018-03-08       Impact factor: 5.923

8.  Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.

Authors:  Jagdeep Nanchahal; Catherine Ball; Dominique Davidson; Lynn Williams; William Sones; Fiona E McCann; Marisa Cabrita; Jennifer Swettenham; Neil J Cahoon; Bethan Copsey; E Anne Francis; Peter C Taylor; Joanna Black; Vicki S Barber; Susan Dutton; Marc Feldmann; Sarah E Lamb
Journal:  EBioMedicine       Date:  2018-07-06       Impact factor: 8.143

Review 9.  The La-related proteins: structures and interactions of a versatile superfamily of RNA-binding proteins.

Authors:  Anne-Catherine Dock-Bregeon; Karen A Lewis; Maria R Conte
Journal:  RNA Biol       Date:  2019-12-03       Impact factor: 4.652

10.  Blood-brain barrier leakage and perivascular collagen accumulation precede microvessel rarefaction and memory impairment in a chronic hypertension animal model.

Authors:  Esra Özkan; Yağmur Çetin-Taş; Emine Şekerdağ; Ali B Kızılırmak; Ali Taş; Erdost Yıldız; Hale Yapıcı-Eser; Serçin Karahüseyinoğlu; Müjdat Zeybel; Yasemin Gürsoy-Özdemir
Journal:  Metab Brain Dis       Date:  2021-06-12       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.